| scholarly article | Q13442814 |
| P50 | author | Eva Lion | Q82252383 |
| P2093 | author name string | Sébastien Anguille | |
| Heleen H Van Acker | |||
| Viggo F Van Tendeloo | |||
| P2860 | cites work | Regulatory dendritic cells for immunotherapy in immunologic diseases | Q26866216 |
| γδ-T cells: an unpolished sword in human anti-infection immunity | Q26994963 | ||
| Six-of-the-best: unique contributions of γδ T cells to immunology | Q27010451 | ||
| Diversity of γδ T-cell antigens | Q27021646 | ||
| γδ T cells for cancer immunotherapy: A systematic review of clinical trials | Q27021705 | ||
| Defining the nature of human γδ T cells: a biographical sketch of the highly empathetic | Q27026152 | ||
| Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? | Q28287583 | ||
| Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities | Q30317871 | ||
| DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells | Q33436859 | ||
| Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies | Q33451518 | ||
| Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients | Q33617841 | ||
| A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human gammadelta T lymphocytes | Q34002174 | ||
| Cellular and molecular basis of human gamma delta T cell activation. Role of accessory molecules in alloactivation | Q34195614 | ||
| HIV infection of monocytes-derived dendritic cells inhibits Vγ9Vδ2 T cells functions | Q34395668 | ||
| Full restoration of Brucella-infected dendritic cell functionality through Vγ9Vδ2 T helper type 1 crosstalk | Q34395849 | ||
| Clinical use of dendritic cells for cancer therapy. | Q34421850 | ||
| Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy | Q34681370 | ||
| The plasticity of gamma delta T cells: innate immunity, antigen presentation and new immunotherapy | Q36295498 | ||
| Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells | Q36370502 | ||
| Tumor-derived γδ regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence | Q36625669 | ||
| Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens | Q36732656 | ||
| Human gamma delta T cells: candidates for the development of immunotherapeutic strategies | Q36908780 | ||
| Mechanisms of dendritic cell-based vaccination against infection | Q36919060 | ||
| Gamma delta T cells and dendritic cells: close partners and biological adjuvants for new therapies | Q37017916 | ||
| γδ T cells exhibit multifunctional and protective memory in intestinal tissues. | Q37112109 | ||
| Specific recruitment of γδ regulatory T cells in human breast cancer. | Q37238831 | ||
| Central memory Vgamma9Vdelta2 T lymphocytes primed and expanded by bacillus Calmette-Guérin-infected dendritic cells kill mycobacterial-infected monocytes | Q80819667 | ||
| Lyme arthritis synovial gammadelta T cells instruct dendritic cells via fas ligand | Q81375503 | ||
| Professional antigen-presentation function by human gammadelta T Cells | Q81810232 | ||
| Regulation of acquired immunity by gamma delta T-cell/dendritic-cell interactions | Q82484504 | ||
| A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate | Q83814814 | ||
| Primary MHC-class II(+) cells are necessary to promote resting Vδ2 cell expansion in response to (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate and isopentenyl pyrophosphate | Q85301440 | ||
| STAT3-silenced human dendritic cells have an enhanced ability to prime IFNγ production by both αβ and γδ T lymphocytes | Q87534553 | ||
| Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma | Q37344951 | ||
| Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors | Q37504235 | ||
| How tumors might withstand γδ T-cell attack. | Q37872644 | ||
| γδ T-APCs: a novel tool for immunotherapy? | Q37875768 | ||
| Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside | Q38051730 | ||
| Gammadelta T cells: innately adaptive immune cells? | Q38101588 | ||
| Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy | Q38115438 | ||
| Insights into the Relationship between Toll Like Receptors and Gamma Delta T Cell Responses | Q38240851 | ||
| Interleukin-15: new kid on the block for antitumor combination therapy. | Q38259216 | ||
| Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56(high+) Interferon-α-induced dendritic cells | Q39104547 | ||
| The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner | Q39221795 | ||
| Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells | Q39313746 | ||
| mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. | Q39550591 | ||
| Partial and ineffective activation of V gamma 9V delta 2 T cells by Mycobacterium tuberculosis-infected dendritic cells | Q39686401 | ||
| Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis | Q39714121 | ||
| Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients | Q39850684 | ||
| Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model | Q39953563 | ||
| IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. | Q40134661 | ||
| Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial | Q40297203 | ||
| Early triggering of exclusive IFN-gamma responses of human Vgamma9Vdelta2 T cells by TLR-activated myeloid and plasmacytoid dendritic cells. | Q40381596 | ||
| Monocytes differentiated with GM-CSF and IL-15 initiate Th17 and Th1 responses that are contact-dependent and mediated by IL-15. | Q40543232 | ||
| Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties | Q41945985 | ||
| Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy | Q42573316 | ||
| Zoledronate Stimulates γδ T Cells in Prostate Cancer Patients | Q42948400 | ||
| In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients | Q43057295 | ||
| (E)-4-hydroxy-3-methyl-but-2 enyl pyrophosphate-stimulated Vgamma9Vdelta2 T cells possess T helper type 1-promoting adjuvant activity for human monocyte-derived dendritic cells. | Q43122508 | ||
| CD56+ human blood dendritic cells effectively promote TH1-type gammadelta T-cell responses | Q43275128 | ||
| Gammadelta T cells and the lymphoid stress-surveillance response | Q43496487 | ||
| Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid | Q44020395 | ||
| Tripartite immune cell co-operation in the Bacillus Calmette Guérin-induced activation of γδ T cells | Q44732034 | ||
| Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. | Q44767879 | ||
| Polyinosinic-polycytidylic acid-mediated stimulation of human gammadelta T cells via CD11c dendritic cell-derived type I interferons | Q44935584 | ||
| Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines | Q45195924 | ||
| Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. | Q46004947 | ||
| Coculture with dendritic cells promotes proliferation but not cytotoxic activity of gamma/delta T cells | Q46490739 | ||
| Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation | Q46835301 | ||
| Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation | Q46902168 | ||
| Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy? | Q47601332 | ||
| Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells. | Q50783387 | ||
| Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. | Q51991785 | ||
| Human γδ thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2/IL-15 signaling. | Q54380279 | ||
| Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between V 9V 2 T Cells, CD8+ T Cells, Regulatory T Cells, and Dendritic Cells | Q60617040 | ||
| Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma | Q73971334 | ||
| Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions | Q74179201 | ||
| In vitro interactions between gamma deltaT cells, DC, and CD4+ T cells; implications for the immunotherapy of leukemia | Q74654435 | ||
| Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation | Q80196080 | ||
| P433 | issue | 8 | |
| P921 | main subject | dendritic cell | Q506253 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | e1021538 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy | |
| P478 | volume | 4 |
| Q39138688 | Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer |
| Q92126900 | CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15 |
| Q40101148 | CD56 in the Immune System: More Than a Marker for Cytotoxicity? |
| Q54974328 | Correction to: Gamma-delta (γδ) T cells: friend or foe in cancer development? |
| Q91613560 | Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia |
| Q90226287 | Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer |
| Q55174561 | Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. |
| Q39014899 | Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells. |
| Q64057109 | Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth |
| Q47742552 | Gamma-delta (γδ) T cells: friend or foe in cancer development? |
| Q36734208 | Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate |
| Q28068788 | Immunotherapy in human colorectal cancer: Challenges and prospective |
| Q37606871 | Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer |
| Q92704668 | In the Absence of a TCR Signal IL-2/IL-12/18-Stimulated γδ T Cells Demonstrate Potent Anti-Tumoral Function Through Direct Killing and Senescence Induction in Cancer Cells |
| Q37294760 | Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells |
| Q52716912 | Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion. |
| Q88550356 | Low dose gemcitabine increases the cytotoxicity of human Vγ9Vδ2 T cells in bladder cancer cells in vitro and in an orthotopic xenograft model |
| Q37701514 | Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma |
| Q37212146 | Necroptosis of Dendritic Cells Promotes Activation of γδ T Cells. |
| Q55198257 | Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon. |
| Q38787725 | Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer |
| Q53109846 | Trial watch: Dendritic cell-based anticancer immunotherapy. |
| Q28068988 | γδ T cells in cancer immunotherapy |
Search more.